Bone marrow aspirate concentrate yields improvements for patients with cartilage damage
Click Here to Manage Email Alerts
Patients who underwent arthroscopic acetabular labral repair for cartilage damage with bone marrow aspirate concentrate had “significantly greater functional improvements” than those without bone marrow aspirate concentrate, results showed.
Scott D. Martin, MD, and investigators at the department of orthopedic surgery at Massachusetts General Hospital analyzed a cohort of 62 patients who received bone marrow aspirate concentrate (BMAC) during arthroscopic acetabular labral repair from December 2016 to June 2019 and a matched cohort of 62 patients who underwent the procedure without BMAC.
According to the study, patient-reported outcome measures (PROMs) were completed prior to surgery and at 3-, 6-, 12- and 24-month follow-up intervals. Researchers also performed a subgroup analysis of patients with moderate cartilage damage who received BMAC.
Overall, researchers found no differences in mean International Hip Outcome Tool-33 (iHOT-33) scores at any follow-up interval between patients who received BMAC and those who did not. However, patients with cartilage damage who received BMAC reported “significantly greater” mean iHOT-33 scores compared with those who did not receive BMAC at 12-month follow-up (78.6 vs. 69.2, respectively) and at 24-month follow-up (82.5 vs. 69.5, respectively).
“Patients with Outerbridge grade 2 or 3 osteoarthritis (OA) reported significantly greater improvements in all PROMs at the 12-month and 24- month follow-up,” the researchers wrote in the study. “These results have important clinical implications, as adjuvant BMAC application alongside hip arthroscopy seems to provide a benefit for selected patients with moderate osteoarthritis, who historically have had inferior outcomes following hip arthroscopy,” they wrote.
Collapse
Read more about
Click Here to Manage Email Alerts